Cizzle Biotechnology is focusing on the gene Ciz1 and its variant, found in small-cell lung cancer. The trigger for the start-up's formation was the finding that cells require Ciz1 to grow, and that variant forms could be used for selective targeting of cancer cells, especially small-cell lung cancer. The company's founders have shown that blocking the disrupted form of Ciz1, using a small interfering RNA (siRNA) targeted to the variant, prevented cell proliferation and growth in vitro. The specificity of the Ciz1 variant also gives it potential as a biomarker for early detection of lung cancer.

As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date. 

Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.